0001209191-22-020076.txt : 20220318 0001209191-22-020076.hdr.sgml : 20220318 20220318173239 ACCESSION NUMBER: 0001209191-22-020076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220317 FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROYSTON IVOR CENTRAL INDEX KEY: 0001026765 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 22753591 MAIL ADDRESS: STREET 1: 4401 WILSHIRE BLVD. STREET 2: SUITE 200 CITY: LOS ANGELES STATE: CA ZIP: 90010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-17 0 0001061027 Viracta Therapeutics, Inc. VIRX 0001026765 ROYSTON IVOR C/O VIRACTA THERAPEUTICS, INC. 2533 S COAST HWY 101, SUITE 210 CARDIFF CA 92007 1 1 0 0 CEO & President Stock Option (Right to Buy) 3.04 2022-03-17 4 A 0 412500 0.00 A 2032-03-17 Common Stock 412500 412500 D One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. /s/ Daniel Chevallard, as Attorney-in-Fact 2022-03-18 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Viracta Therapeutics, Inc. (the "Company"), hereby constitutes and appoints Daniel Chevallard, Stewart Brown, Shelly Vandertie, Ben Capps, and Brandon Shaw the undersigned's true and lawful attorneys-in-fact to: 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of March, 2022. Signature: /s/ Ivor Royston Print Name: Ivor Royston